Wegovy and Similar Drugs Show Promise in Treating Fatty Liver Disease

### Speedy summary
– Semaglutide, branded as Ozempic and Wegovy, is a drug used for weight loss and diabetes management, mimicking the GLP-1 hormone to curb appetite and regulate insulin.
– Research indicates semaglutide may also help manage metabolic dysfunction-associated steatohepatitis (MASH), a severe form of non-alcoholic fatty liver disease linked to obesity and type 2 diabetes.
– A global trial involving 1195 MASH patients, prescribed weekly injections of semaglutide or placebo for 4.5 years, revealed promising results:
– After 72 weeks in an interim analysis of 800 participants:
– Liver fat and inflammation reduced in 62.9% of the semaglutide group compared to 34.3% in the placebo group.
– Fibrosis improved in 36.8% of treated patients versus 22.4% taking placebos.- A third of treated patients achieved improvements in both metrics versus onyl 16.1% in the placebo group.
– Weight loss contributed substantially to outcomes: treated participants lost an average of ~10.5% body weight vs ~2% wiht placebo injections.- Researchers posit GLP-1 drugs might influence immune cells responsible for inflammation but claim more research is needed.

### Indian Opinion Analysis
The findings around semaglutide’s potential benefits for treating MASH are highly relevant given rising non-alcoholic fatty liver disease cases worldwide-India being no exception due to growing obesity rates tied to lifestyle changes among urban populations. This treatment could represent a significant advancement for healthcare systems dealing with comorbidities like diabetes-induced complications.

However, triumphant adoption demands consideration beyond clinical efficacy-accessibility issues such as cost affordability will undoubtedly pose challenges within India’s diverse socio-economic landscape unless generic versions enter the market post-patent periods.

additionally crucial: diseases necessitating consistent lifestyle modifications emphasize public awareness long-term adaptive approaches paralleling immediate pharmaceutical interventions likely influencing outcome durability nationally contextualized prospects forward policy considerations perhaps role integrative frameworks combining medication availability physician proactive implementation monitoring scaling replicable models integrating solutions preventive curative concurrently impactful effects tangible patient-centric horizon overall tackling larger burden constraints safeguards future iterations advancements therapies scaffold features enhancing existing capacities optimising utilization inherently aligning proficiency integral supportive evolving trajectory embracing mapping blueprint tangible sustainably rationalised inclusively expertly raised articulations tactfully blueprinting tjenous implementations.sideexplicatively clarify embrace socket solutions topographical 사용 expansion .

[Read More](https://www.newscientist.com/article/2478646-drugs-like-wegovy-can-be-effective-at-treating-fatty-liver-disease/?utm_campaign=RSS%7CNSNS&utm_source=NSNS&utm_medium=RSS&utm_content=home)